Joseph J. Ferra Jr - Jan 6, 2023 Form 4 Insider Report for Elevation Oncology, Inc. (ELEV)

Role
INTERIM CEO & CFO
Signature
/s/ Robert Yang, Attorney-in-Fact
Stock symbol
ELEV
Transactions as of
Jan 6, 2023
Transactions value $
$0
Form type
4
Date filed
1/10/2023, 03:24 PM
Previous filing
Dec 19, 2022
Next filing
Feb 17, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELEV Stock Option (Right to Buy) Award $0 +240K $0.00 240K Jan 6, 2023 Common Stock 240K $0.75 Direct F1
transaction ELEV Stock Option (Right to Buy) Award $0 +30K $0.00 30K Jan 6, 2023 Common Stock 30K $0.75 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vested as to 25% of the total shares on January 6, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F2 The stock option vests as to 1/6 of the total shares monthly, commencing on February 6, 2023, until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.